Target Name: TENT4A
NCBI ID: G11044
Review Report on TENT4A Target / Biomarker Content of Review Report on TENT4A Target / Biomarker
TENT4A
Other Name(s): LAK1 | Terminal uridylyltransferase 5 | polymerase (DNA directed) sigma | TUTASE5 | POLS | TUTase 5 | Topoisomerase-related function protein 4-1 | non-canonical poly(A) RNA polymerase PAPD7 | poly(A) RNA polymerase D7, non-canonical | TENT4A variant 1 | TRF41 | TRAMP-like complex polyadenylate polymerase | DNA polymerase kappa | DNA-directed DNA polymerase | terminal guanylyltransferase | Terminal nucleotidyltransferase 4A isoform 1 | LAK-1 | terminal nucleotidyltransferase 4A | PAPD7_HUMAN | PAPD7 | terminal uridylyltransferase 5 | Terminal nucleotidyltransferase 4A | DNA polymerase sigma | TRF4-1 | OTTHUMP00000115520 | TRF4 | POLK | Terminal nucleotidyltransferase 4A, transcript variant 1 | DNA nucleotidyltransferase | Polymerase (DNA-directed) sigma | PAP-associated domain-containing protein 7 | topoisomerase-related function protein 4-1 | Terminal guanylyltransferase | DNA-dependent DNA polymerase

TENT4A: A Promising Drug Target and Biomarker for ALZHEIMER'S DISEASE

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide, primarily in old age. It is characterized by the accumulation of neurofibrillary tangles and senile plaques in the brain, leading to the gradual decline in cognitive abilities, including memory, language, and decision-making. Currently, there is no cure for Alzheimer's disease, and numerous treatments are either limited in their effectiveness or have potential adverse effects. Therefore, identifying new drug targets and biomarkers is crucial for the development of more effective therapies. TENT4A, a gene encoding a protein called TARZ, has been identified as a promising drug target and biomarker for Alzheimer's disease.

The Protein TENT4A and Its Functions

TENT4A is a member of the TARZ family, which includes proteins involved in various cellular processes, including cell adhesion, migration, and stress response. The TARZ family has been implicated in the development and progression of various diseases, including Alzheimer's disease. The accumulation of neurofibrillary tangles and senile plaques in Alzheimer's disease is thought to involve the misfolding and mislocalization of TARZ proteins, leading to their aggregation and formation of tangles.

Recent studies have suggested that TENT4A plays a crucial role in the development and progression of Alzheimer's disease. For example, overexpression of TENT4A has been shown to promote the formation of neurofibrillary tangles and senile plaques in animal models of Alzheimer's disease. Similarly, human studies have shown that individuals with higher levels of TENT4A are more likely to have Alzheimer's disease, as well as poor cognitive function and memory.

Drug Targeting TENT4A

The identification of TENT4A as a potential drug target has led to a great deal of interest in developing small molecules that can inhibit its activity. Currently, several compounds have been shown to inhibit TENT4A's activity, including inhibitors of the enzyme tyrosine aminotransferase (TAT), which is involved in the folding and localization of TARZ proteins.

One of the most promising compounds is a small molecule called NX1027, which is a novel inhibitor of TAT. NX1027 has been shown to block the accumulation of neurofibrillary tangles and senile plaques in animal models of Alzheimer's disease, and may be a useful candidate for human clinical trials. Another compound that has shown promise is a peptide called P3, which contains a unique calbindin-like domain that can interact with TENT4A and inhibit its activity.

Biomarker Analysis

While drug targeting TENT4A is an exciting development, it is important to also identify biomarkers that can be used to monitor the progression of Alzheimer's disease. One such biomarker is the protein beta-amyloid, which is thought to play a crucial role in the development and progression of Alzheimer's disease.

Recent studies have shown that individuals with Alzheimer's disease have lower levels of beta-amyloid in their brains than those without the disease. Therefore, measuring the levels of beta-amyloid in brain tissue or plasma may be an effective biomarker for Alzheimer's disease. Several studies have shown that beta-amyloid levels can be increased using various methods, including the use of antibodies to specifically target beta-amyloid.

Another biomarker that has potential in monitoring the progression of Alzheimer's disease is the neurofibrillary tangles and senile plaques, which were discussed earlier. The accumulation of these structures in the brain is thought to be a key indicator of the severity and progression of

Protein Name: Terminal Nucleotidyltransferase 4A

Functions: Terminal nucleotidyltransferase that catalyzes preferentially the transfert of ATP and GTP on RNA 3' poly(A) tail creating a heterogeneous 3' poly(A) tail leading to mRNAs stabilization by protecting mRNAs from active deadenylation (PubMed:23376078, PubMed:30026317). Also functions as a catalytic subunit of a TRAMP-like complex which has a poly(A) RNA polymerase activity and is involved in a post-transcriptional quality control mechanism. Polyadenylation with short oligo(A) tails is required for the degradative activity of the exosome on several of its nuclear RNA substrates. Has no terminal uridylyltransferase activity, and does not play a role in replication-dependent histone mRNA degradation via uridylation (PubMed:23376078)

The "TENT4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TENT4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TENT4B | TENT5A | TENT5B | TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI | TFPI2